title: Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
abstract: High costs of molecule-targeted drugs, such as rituximab, ibritumomab, and tositumomab have given rise to an economical issue for treating patients with non-Hodgkin's lymphoma (NHL). Granulocyte colony-stimulating factors (G-CSFs), which are also expensive, are widely used for treating neutropenia after chemotherapy. In Japan, lenograstim at 2 microg/kg (about 100 microg/body) or filgrastim at 50 microg/m(2) (about 75 microg/body) is commonly administered for patients with NHL after chemotherapy. Therefore, cost-effectiveness is an important issue in treatment for NHL. Patients with advanced-stage NHL who needed chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen with or without rituximab were enrolled in this randomized cross-over trial to investigate the efficacy and safety of low-dose G-CSF. Half of the patients were administered 75 microg filgrastim in the first course after neutropenia and 50 microg lenograstim in the second course, and the other half were crossed over. Forty-seven patients were enrolled in this cross-over trial, and 24 patients completed the trial. Frequencies and durations of grade 4 leukocytopenia and neutropenia were similar in the two groups. Severe infection was rare and was observed at similar frequency. Frequencies of antibiotics use were also similar. The total cost of G-CSF (cost/drug x duration of administration) was significantly lower in patients who received 50 microg lenograstim. Hence, a low dose of lenograstim might be safe, effective and pharmaco-economically beneficial in patients with advanced-stage NHL.
authors.affiliation: Department of Gastroenterology and Hematology, Hokkaido University School of Medicine, Sapporo, Japan. shashino@med.hokudai.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Hashino
authors.forename: M
authors.initials: M
authors.lastname: Morioka
authors.forename: T
authors.initials: T
authors.lastname: Irie
authors.forename: N
authors.initials: N
authors.lastname: Shiroshita
authors.forename: T
authors.initials: T
authors.lastname: Kawamura
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: S
authors.initials: S
authors.lastname: Umehara
authors.forename: Y
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: M
authors.initials: M
authors.lastname: Kurosawa
authors.forename: K
authors.initials: K
authors.lastname: Kahata
authors.forename: K
authors.initials: K
authors.lastname: Izumiyama
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Onozawa
authors.forename: M
authors.initials: M
authors.lastname: Takahata
authors.forename: F
authors.initials: F
authors.lastname: Fujisawa
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: M
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D018592:Cross-Over Studies; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D000078224:Lenograstim; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim